BT in the 2 subtypes
| BT, n (%) . | HGBL (N = 78) . | DLBCL (N = 354) . | P value . |
|---|---|---|---|
| No | 4 (5) | 75 (21) | <.001 |
| Yes | 74 (95) | 279 (79) | |
| BT therapies | |||
| Chemoimmunotherapy∗ | 34 (46) | 172 (62) | |
| Radiotherapy | 17 (23) | 52 (19) | |
| Chemotherapy + radiotherapy | 10 (14) | 18 (6) | |
| Others | 9 (12) | 22 (8) | |
| Missing | 4 (5) | 15 (5) | |
| Antibody drug conjugate | |||
| Polatuzumab-based (included in chemoimmunotherapy) | 15 (20) | 61 (22) |
| BT, n (%) . | HGBL (N = 78) . | DLBCL (N = 354) . | P value . |
|---|---|---|---|
| No | 4 (5) | 75 (21) | <.001 |
| Yes | 74 (95) | 279 (79) | |
| BT therapies | |||
| Chemoimmunotherapy∗ | 34 (46) | 172 (62) | |
| Radiotherapy | 17 (23) | 52 (19) | |
| Chemotherapy + radiotherapy | 10 (14) | 18 (6) | |
| Others | 9 (12) | 22 (8) | |
| Missing | 4 (5) | 15 (5) | |
| Antibody drug conjugate | |||
| Polatuzumab-based (included in chemoimmunotherapy) | 15 (20) | 61 (22) |
Boldface highlights the patients who had received bridging therapy.
Monotherapy (single chemotherapy drug) was used in 3 patients with HGBL and in 34 with DLBCL, respectively.